Clinical Characteristics and Prognosis of Patients with IgD Multiple Myeloma.
10.19746/j.cnki.issn.1009-2137.2025.02.018
- Author:
Yong-Qian ZHANG
1
;
Ji-Sheng ZHAO
1
;
Xiao-Fang WEI
2
;
You-Fan FENG
2
;
Yuan FU
2
;
Qiao-Lin CHEN
2
;
Qi-Ke ZHANG
2
Author Information
1. Department of Hematology, Qingyang People's Hospital, Qingyang 745000, Gansu Province, China.
2. Department of Hematology, Gansu Provincial Hospital, Lanzhou 730000, Gansu Province, China.
- Publication Type:Journal Article
- Keywords:
IgD multiple myeloma;
IgD-λ;
IgD-κ;
clinical characteristics;
prognosis
- MeSH:
Humans;
Multiple Myeloma/therapy*;
Middle Aged;
Male;
Female;
Aged;
Prognosis;
Immunoglobulin D;
Adult;
Retrospective Studies
- From:
Journal of Experimental Hematology
2025;33(2):437-441
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the clinical characteristics and prognosis of patients with IgD multiple myeloma (MM).
METHODS:The clinical data of 8 patients with IgD MM admitted to Gansu Provincial Hospital from September 2013 to February 2023 were collected, and their clinical characteristics and prognosis were retrospectively analyzed and summarized.
RESULTS:Among the 8 enrolled patients, there were 4 males and 4 females, with a median age of 60 (44-74) years. All patients had symptoms of renal insufficiency and anemia. There were 3 cases of bone invasion, 3 cases of splenomegaly, 7 cases of IgD-λ type, and 1 case of IgD-κ type. FISH examination was performed in 7 cases, and 6 of them were positive for 1q21 . There were 6 cases in DS stage III and 2 cases in DS stage II; According to ISS staging, there were 6 cases in stage III, 1 case in stage II, and 1 case in stage I; According to R-ISS staging, there were 5 cases in stage III and 3 cases in stage II. All patients received bortezomib-based combination chemotherapy, with 1 case undergoing autologous stem cell transplantation (ASCT) and 2 cases receiving daratumumab in combination. The median treatment period was 6 (1-15) cycles. The short-term efficacy was evaluated after 4-6 courses of treatment. Among the 6 patients with assessable efficacy, 1 case experienced disease progression (PD), and 5 cases achieved complete remission (CR). The median follow-up time was 26 (11-33) months, and the median progression-free survival (PFS) and median overall survival (OS) of the patients were 11.25 (3-26) months and 18.5 (4-33) months, respectively. Among the 8 patients, 4 cases died. Among the deceased patients, 3 cases were in R-ISS stage III and 3 cases were 1q21 positive. 2 of the 5 patients with early CR died due to disease progression.
CONCLUSION:The incidence of IgD MM is low, the symptoms of early renal damage, blood system damage and bone erosion in IgD MM patients are obvious, and the median survival time is short. ASCT and / or daratumumab may bring lasting relief for IgD MM patients, but large-scale clinical studies are still needed.
